|
Rectal Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Finally, ASCL2 expression was significantly correlated with histological grade of rectal cancer with preoperative chemoradiation therapy.
|
30706227 |
2019 |
|
Colitis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Notably, lentivirus-mediated overexpression of Ascl2 remarkably alleviated the severity of 2,4,6-trinitrobenzenesulfonic acid solution (TNBS)-induced colitis in mice, with decreased level of colonic IL-17A.
|
30722992 |
2019 |
|
Inflammatory Bowel Diseases
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Here, we demonstrated that Ascl2 was greatly down-regulated in human IBD and experimental colitis.
|
30722992 |
2019 |
|
Carcinogenesis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
The enhanced WiNTRLINC1/ASCL2/c-Myc axis involved in Wnt pathway activation is a common pathway essential for differentiated colon tumorigenesis, especially with young onset, and may be essential for a viable phenotype of colon cancer.
|
31549316 |
2019 |
|
Adenoma of large intestine
|
0.010 |
Biomarker
|
disease |
BEFREE |
In the Immunotherapy Study, fewer colon adenomas tended to be observed in recMASH2+AS15-treated mice (4.1 [2.9-6.0]) compared to controls (AS15 4.7 [3.3-6.6]; PBS 4.9 [3.5-6.9]; no significant difference). recMASH2+AS15 induced MASH2-specific antibody and CD4+ responses in both mouse models. recMASH2+AS15 partially protected mice against MASH2-expressing tumors and reduced spontaneous colorectal adenomas in Apc+/Min-FCCC mice, indicating that MASH2/HASH2 antigens are targets for colorectal cancer immunotherapy.
|
30682058 |
2019 |
|
Multiple Sclerosis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
In summary, our results suggest that ASCL2 mediates the protective function of rs1335532 minor (C) allele in MS.
|
30006149 |
2018 |
|
Malignant neoplasm of breast
|
0.010 |
Biomarker
|
disease |
BEFREE |
Altogether, our study suggests that ASCL2 defines a subgroup of highly progressive breast cancer and serves as a marker to evaluate the risk of cancer relapse.
|
28469967 |
2017 |
|
B-Cell Lymphomas
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Overexpression of Ascl2 also increased the expression of proinflammatory cytokines and chemoattractants including interleukin 6 (IL-6), tumor necrosis factor-α, IL-8, programmed cell death 1 (PD-1), IL-21, and B-cell lymphoma 6 (Bcl-6).
|
28728856 |
2017 |
|
Tumor Progression
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
In this study, we evaluated the expression of ASCL2 and its relationship to cancer progression in specimens from 191 cases of breast cancer patients with follow-up information.
|
28469967 |
2017 |
|
Breast Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Altogether, our study suggests that ASCL2 defines a subgroup of highly progressive breast cancer and serves as a marker to evaluate the risk of cancer relapse.
|
28469967 |
2017 |
|
Cancer Relapse
|
0.010 |
Biomarker
|
disease |
BEFREE |
Altogether, our study suggests that ASCL2 defines a subgroup of highly progressive breast cancer and serves as a marker to evaluate the risk of cancer relapse.
|
28469967 |
2017 |
|
Mammary Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Moreover, the expression of ASCL2 was positively correlated with breast tumor size, lymphatic metastasis and the active growth of tumor cells as shown by increased expression of Ki67.
|
28469967 |
2017 |
|
Malignant neoplasm of endometrium
|
0.010 |
Biomarker
|
disease |
BEFREE |
Age-adjusted odds ratios for endometrial cancer ranged from 3.44 (95%-CI: 1.33-8.91) for ASCL2 to 18.61 (95%-CI: 5.50-62.97) for HTR1B.
|
24623538 |
2014 |
|
Endometrial Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Age-adjusted odds ratios for endometrial cancer ranged from 3.44 (95%-CI: 1.33-8.91) for ASCL2 to 18.61 (95%-CI: 5.50-62.97) for HTR1B.
|
24623538 |
2014 |
|
Adenoma
|
0.010 |
Biomarker
|
group |
BEFREE |
Wnt/Tcf, Lgr5, Ascl2 and/or Bmi1 signalling is believed to define the mouse intestinal stem cell niche(s) from which adenomas arise.
|
22637696 |
2013 |
|
Carcinoma
|
0.010 |
Biomarker
|
group |
BEFREE |
Therefore, we investigated dimethylation of histone H3 at lysine 4 (H3K4diMe) and H3K4 methylating (Ash2 complex) and demethylating enzymes (LSD1) in carcinomas of the hepatic and gastrointestinal tract.
|
19896696 |
2010 |
|
Secondary malignant neoplasm of liver
|
0.010 |
Biomarker
|
disease |
BEFREE |
In addition, we characterised a subset of liver metastases with an ASCL2-related stem-cell signature likely to affect metastatic behaviour of tumour cells.
|
20479215 |
2010 |
|
Liver carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Ash2 was expressed in 84.4% of hepatocellular carcinomas (38/45) and correlated directly with H3K4diMe modification (correlation coefficient r = 0.53) and LSD1 expression (r = 0.35).
|
19896696 |
2010 |
|
Hydatidiform Mole, Invasive
|
0.010 |
AlteredExpression
|
disease |
LHGDN |
Negative expression of HASH2 in CM but positive expression in malignant tumors suggests the presence of a specific mechanism for inactivation of the HASH2 gene in CM and reactivation in IvM or ChCa.
|
17165436 |
2006 |
|
Choriocarcinoma
|
0.010 |
AlteredExpression
|
disease |
LHGDN |
Negative expression of HASH2 in CM but positive expression in malignant tumors suggests the presence of a specific mechanism for inactivation of the HASH2 gene in CM and reactivation in IvM or ChCa.
|
17165436 |
2006 |
|
Hydatidiform Mole
|
0.010 |
AlteredExpression
|
disease |
LHGDN |
Detection of HASH2 (ASCL2) gene expression in gestational trophoblastic disease.
|
17165436 |
2006 |
|
Anoxia
|
0.010 |
AlteredExpression
|
phenotype |
LHGDN |
In this study, we found that trophoblast nuclear protein binding to these E boxes declined with syncytiotrophoblast differentiation in 20% O(2) and was induced by hypoxia; however, Mash-2 did not appear to bind to any of these E boxes.
|
12917334 |
2003 |
|
Autoimmune Diseases
|
0.020 |
Biomarker
|
group |
BEFREE |
In conclusion, our results indicate that abnormal Tfh cell differentiation via Ascl2 regulation might contribute to the pathogenesis of autoimmunity.
|
31539517 |
2019 |
|
Autoimmune Diseases
|
0.020 |
Biomarker
|
group |
BEFREE |
Ascl2 (achaete-scute complex homologue 2), identified as a homologue of the Drosophila achaete-scute gene, has been shown to play an essential for the pathogenesis of autoimmune diseases and cancers.
|
30722992 |
2019 |
|
Sjogren's Syndrome
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Comprehensive gene analysis revealed that several genes associated with Tfh cell differentiation, including achaete-scute homologue 2 (Ascl2), were up-regulated in peripheral CD25<sup>-</sup> CD4<sup>+</sup> T cells in SS model mice compared with those in control mice.
|
31539517 |
2019 |